This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those taking GLP-1 receptor agonists.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ...

This opens the door to making mistakes—ones that could worsen your side effects, affect how much weight you’ll lose, or even ...

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

“This is a miracle,” the 51-year-old tells Women's Health.

Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor being developed to treat obesity, delivered positive results.

However, not everyone is willing—or able—to indefinitely commit to GLP-1s.

Glucagon, secreted by pancreatic α-cells, plays a crucial role in glucose metabolism through its counter-regulatory effects ...

As GLP-1 drugs become more available, some people might use them despite not having excess weight.

An estimated 60% of patients with Alzheimer's disease develop epilepsy or subclinical epileptiform activity over the course of the disease. New-onset seizures in cognitively healthy adults also ...